Patents by Inventor Zhuoru Liu
Zhuoru Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10670603Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.Type: GrantFiled: May 31, 2017Date of Patent: June 2, 2020Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
-
Publication number: 20170327591Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.Type: ApplicationFiled: May 31, 2017Publication date: November 16, 2017Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
-
Patent number: 9696312Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.Type: GrantFiled: September 4, 2012Date of Patent: July 4, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
-
Publication number: 20150110714Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.Type: ApplicationFiled: September 4, 2012Publication date: April 23, 2015Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
-
Publication number: 20090280109Abstract: This invention provides compositions which comprise at least two of a CD4+CD25+ cell, IL-10, a CD8+CD28? cell and a vitamin D3 analog. This invention also provides methods for generating a tolerogenic antigen-presenting cell, and increasing the expression of ILT3 and/or ILT4 by an antigen-presenting cell. This invention further provides methods for inhibiting the onset of or treating the rejection of an antigenic substance and inhibiting the onset of or treating an autoimmune disease in a subject. This invention further provides methods for treating and preventing AIDS, cancer, and Hepatitis C-related disorders, and for identifying agents useful for such purposes. Finally, this invention provides related compositions and kits.Type: ApplicationFiled: February 22, 2008Publication date: November 12, 2009Applicant: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, Zhuoru Liu, Chih-Chao Chang, Raffaello Cortesini
-
Patent number: 7144728Abstract: This invention also provides a method of generating antigen specific human suppressor CD8+CD28? T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28? T cells. Methods of tent for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28? T cells so produced are also provided, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.Type: GrantFiled: June 15, 2000Date of Patent: December 5, 2006Assignee: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, Raffaello Cortesini, Zhuoru Liu, Chih-Chao Chang
-
Publication number: 20050250161Abstract: This invention provides a method of generating antigen specific allospecific human-suppressor CD8+CD28? T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28? T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28? T cells. Methods of treatment for, reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28? T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.Type: ApplicationFiled: July 2, 2004Publication date: November 10, 2005Applicant: The Trustees of Columbia UniversityInventors: Nicole Suciu-Foca, Raffaello Cortesini, Zhuoru Liu, Chih-Chao Chang
-
Publication number: 20040241167Abstract: This invention provides compositions which comprise at least two of a CD4+CD25+ cell, IL-10, a CD8+CD28− cell and a vitamin D3 analog. This invention also provides methods for generating a tolerogenic antigen-presenting cell, and increasing the expression of ILT3 and/or ILT4 by an antigen-presenting cell. This invention further provides methods for inhibiting the onset of or treating the rejection of an antigenic substance and inhibiting the onset of or treating an autoimmune disease in a subject. This invention further provides methods for treating and preventing AIDS, cancer, and Hepatitis C-related disorders, and for identifying agents useful for such purposes. Finally, this invention provides related compositions and kits.Type: ApplicationFiled: June 24, 2004Publication date: December 2, 2004Inventors: Nicole Suciu-Foca, Zhuoru Liu, Chih-Chao Chang, Raffaello Cortesini
-
Patent number: 6759239Abstract: This invention provides a method of generating antigen specific allospecific human suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of treatment for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.Type: GrantFiled: December 21, 2000Date of Patent: July 6, 2004Assignee: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, Raffaello Cortesini, Zhuoru Liu, Chih-Chao Chang